

# Harald Holte

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2298448/publications.pdf>

Version: 2024-02-01

209  
papers

17,407  
citations

76326

40  
h-index

14208

128  
g-index

210  
all docs

210  
docs citations

210  
times ranked

14865  
citing authors

#	ARTICLE	IF	CITATIONS
1	Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 629-639.	27.0	243
2	Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. <i>Blood</i> , 2022, 139, 1863-1877.	1.4	43
3	Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life. <i>Haematologica</i> , 2022, 107, 2698-2707.	3.5	6
4	Subcutaneous epcoritamab with rituximab + lenalidomide ( $R^{2}$ ) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 7524-7524.	1.6	12
5	Low lymphocyte-to-monocyte ratio predicts poor outcome in high-risk aggressive large B-cell lymphoma. <i>EJHaem</i> , 2022, 3, 681-687.	1.0	1
6	Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 718-729.	3.5	75
7	Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress. <i>Bone Marrow Transplantation</i> , 2021, 56, 968-970.	2.4	3
8	The DLBCL90 gene expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma. <i>EJHaem</i> , 2021, 2, 107-111.	1.0	1
9	Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , 2021, 13, 398.	3.7	16
10	A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma. <i>Med</i> , 2021, 2, 180-195.e5.	4.4	0
11	Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2502-2506.	3.5	8
12	A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL. <i>Blood Advances</i> , 2021, 5, 4771-4782.	5.2	10
13	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1403-1415.	10.7	222
14	Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. <i>European Journal of Cancer</i> , 2021, 157, 132-139.	2.8	4
15	Protein Profiling Identify Distinct Tumor-Tissue Protein Expression Pattern Specific for Relapsing Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 4499-4499.	1.4	0
16	Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 3519-3519.	1.4	0
17	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. <i>Blood</i> , 2021, 138, 1326-1326.	1.4	1
18	Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study. <i>Blood</i> , 2021, 138, LBA-6-LBA-6.	1.4	9

#	ARTICLE	IF	CITATIONS
19	No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. <i>British Journal of Haematology</i> , 2020, 188, 685-691.	2.5	16
20	Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016. <i>Acta Oncologica</i> , 2020, 59, 101-105.	1.8	1
21	Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 891-905.	2.4	12
22	Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 4091-4101.	5.2	33
23	The simplified follicular lymphoma PRIMA prognostic index is useful in patients with first-line chemo-free rituximab-based therapy. <i>British Journal of Haematology</i> , 2020, 191, 738-747.	2.5	13
24	Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series. <i>Blood Advances</i> , 2020, 4, 1859-1866.	5.2	7
25	Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. <i>Blood Advances</i> , 2020, 4, 1906-1915.	5.2	35
26	Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 629-637.	5.2	48
27	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. <i>British Journal of Haematology</i> , 2020, 189, 661-671.	2.5	12
28	Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 27-28.	1.4	1
29	Validation of the <sc>MCL</sc>35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. <i>British Journal of Haematology</i> , 2019, 184, 616-624.	2.5	25
30	Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S251-S252.	0.4	3
31	TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. <i>Cancer Immunology Research</i> , 2019, 7, 355-362.	3.4	82
32	Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes. <i>Leukemia</i> , 2019, 33, 2662-2672.	7.2	24
33	Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 1230-1243.	5.2	43
34	Prolonged Improvement in Patient Reported Quality of Life (QoL) Following Tisagenlecleucel Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL): 19-Month Follow-up (FU) of the Juliet Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S181-S182.	2.0	4
35	Reply to M. Sorigue et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 759-760.	1.6	0
36	A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy. <i>Haematologica</i> , 2019, 104, e460-e464.	3.5	5

#	ARTICLE	IF	CITATIONS
37	Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 703-713.	1.6	22
38	Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S20-S21.	2.0	28
39	Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes. <i>Acta Oncologica</i> , 2019, 58, 690-699.	1.8	11
40	Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. <i>Blood Advances</i> , 2019, 3, 2230-2236.	5.2	59
41	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2019, 394, 2271-2281.	13.7	155
42	Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2019, 380, 45-56.	27.0	2,594
43	Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity. <i>Bone Marrow Transplantation</i> , 2019, 54, 607-610.	2.4	12
44	Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel. <i>Blood</i> , 2019, 134, 2883-2883.	1.4	15
45	Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). <i>Blood</i> , 2019, 134, 242-242.	1.4	8
46	Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. <i>Blood</i> , 2019, 134, 4103-4103.	1.4	24
47	Mutational Dynamics and Evolutionary Divergence in DLBCL: A Call for Relapse Sampling. <i>Blood</i> , 2019, 134, 1497-1497.	1.4	0
48	System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival. <i>Blood</i> , 2019, 134, 2897-2897.	1.4	0
49	Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients. <i>Blood</i> , 2019, 134, 4113-4113.	1.4	0
50	Genomic Profiling of Circulating Tumor DNA Reveals Patterns of Response and Refractoriness in Aggressive B-Cell Lymphoma - a Nordic Lymphoma Group Correlative Study. <i>Blood</i> , 2019, 134, 1481-1481.	1.4	1
51	The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy. <i>Blood</i> , 2019, 134, 1485-1485.	1.4	0
52	The role of surgery in intracranial PCNSL. <i>Neurosurgical Review</i> , 2018, 41, 1037-1044.	2.4	19
53	Sample-Index Misassignment Impacts Tumour Exome Sequencing. <i>Scientific Reports</i> , 2018, 8, 5307.	3.3	17
54	Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma. <i>Brain and Behavior</i> , 2018, 8, e00928.	2.2	28

#	ARTICLE	IF	CITATIONS
55	Pre-dosing with lilotomab prior to therapy with <sup>177</sup> Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1233-1241.	6.4	21
56	Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years. <i>Hematological Oncology</i> , 2018, 36, 217-223.	1.7	13
57	Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate <sup>177</sup> Lu-Lilotomab Satetraxetan. <i>Journal of Nuclear Medicine</i> , 2018, 59, 704-710.	5.0	16
58	Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation. <i>Acta Oncologica</i> , 2018, 57, 773-781.	1.8	7
59	Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. <i>Journal of Clinical Oncology</i> , 2018, 36, 3315-3323.	1.6	42
60	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. <i>Blood</i> , 2018, 132, 2401-2405.	1.4	64
61	Efficacy of the Nordic and the MSKCC chemotherapy protocols on the overall and progression-free survival in intracranial PCNSL. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 73, 25-32.	1.4	4
62	Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?. <i>Neuroradiology</i> , 2018, 60, 703-713.	2.2	5
63	Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. <i>Lancet Haematology</i> , 2018, 5, e359-e367.	4.6	74
64	The <sup>35</sup> gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy. <i>British Journal of Haematology</i> , 2018, 183, 225-234.	2.5	24
65	LYMRIT 37-01: A Phase I/II Study of <sup>177</sup> Lu-Lilotomab Satetraxetan (Betalutin®) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) - Analysis with 6-Month Follow-up. <i>Blood</i> , 2018, 132, 2879-2879.	1.4	11
66	Relapse Risk and Loss in Expectation of Lifetime in Young Classical Hodgkin Lymphoma Patients - a Nordic Lymphoma Group Study of 2,582 Patients. <i>Blood</i> , 2018, 132, 930-930.	1.4	1
67	Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA. <i>Blood</i> , 2018, 132, 781-781.	1.4	14
68	The PRIMA-Prognostic Index (PI) Is Valid in Follicular Lymphoma (FL) Patients with Rituximab Chemo-Free First-Line Treatment. <i>Blood</i> , 2018, 132, 4150-4150.	1.4	1
69	Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel. <i>Blood</i> , 2018, 132, 1684-1684.	1.4	28
70	Young High Risk Patients with MYC/BCL2 Double Hit Lymphoma, BCL2+ and/or Germinal Centre B-Cell like Diffuse Large B-Cell Lymphoma Benefit from Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis: Analysis of Data from the Nordic Lymphoma Group CRY-04 and Chic Trials. <i>Blood</i> , 2018, 132, 2955-2955.	1.4	1
71	Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma. <i>Blood</i> , 2018, 132, 4145-4145.	1.4	0
72	Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients. <i>Blood</i> , 2018, 132, 452-452.	1.4	3

#	ARTICLE	IF	CITATIONS
73	Bone mineral density is close to normal for age in long-term lymphoma survivors treated with high-dose therapy with autologous stem cell transplantation. <i>Acta Oncologica</i> , 2017, 56, 590-598.	1.8	7
74	Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2017, 102, e195-e198.	3.5	23
75	Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) – An Interim Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S373-S374.	0.4	13
76	MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2017, 7, 654.	6.2	26
77	Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 623-632.	1.3	5
78	Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate <sup>177</sup> Lu-Lilotomab Satetraxetan. <i>Journal of Nuclear Medicine</i> , 2017, 58, 48-54.	5.0	29
79	Red Marrow – Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with <sup>177</sup> Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody – Radionuclide Conjugate. <i>Journal of Nuclear Medicine</i> , 2017, 58, 55-61.	5.0	22
80	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. <i>Journal of Clinical Oncology</i> , 2017, 35, 1668-1677.	1.6	102
81	A phase II, single-arm, multicentre study of coltuximab ravtansine ( <sup>177</sup> SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 722-730.	2.5	49
82	A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 432-443.	2.5	23
83	The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2016, 175, 102-114.	2.5	56
84	Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation. <i>British Journal of Cancer</i> , 2016, 115, 178-187.	6.4	20
85	Impaired Right Ventricular Function in Long-Term Lymphoma Survivors. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 528-536.	2.8	28
86	Valvular Dysfunction in Lymphoma Survivors Treated With Autologous Stem Cell Transplantation. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 230-239.	5.3	44
87	<sup>177</sup> Lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens. <i>Blood</i> , 2016, 128, 1780-1780.	1.4	2
88	Low Expression and Somatic Mutations of the KLHL6 Gene Predict Poor Survival in Patients with Activated B-Cell like Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2926-2926.	1.4	3
89	Poor Mobilizing Lymphoma Patients Rescued By Addition of Plerixafor during Stem Cell Mobilization Have Equal Survival As Good Mobilizers When Given High Dose Therapy with Autologous Stem Cell Support. <i>Blood</i> , 2016, 128, 5826-5826.	1.4	0
90	Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial). <i>Blood</i> , 2016, 128, 1854-1854.	1.4	2



#	ARTICLE	IF	CITATIONS
91	The Health Related Quality of Life Is Maintained Following Treatment of Indolent Non-Hodgkin's Lymphoma Patients with the Novel Effective Antibody Radionuclide Conjugate <sup>177</sup> Lu-Satetraxetan-Lilotomab. <i>Blood</i> , 2016, 128, 5339-5339.	1.4	0
92	Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway. <i>Haematologica</i> , 2015, 100, e240-e243.	3.5	12
93	Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. <i>Blood</i> , 2015, 125, 82-89.	1.4	45
94	Primary diffuse large B-cell lymphoma associated with clonally-related monoclonal B lymphocytosis indicates a common precursor cell. <i>Haematologica</i> , 2015, 100, e415-e418.	3.5	3
95	Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma. <i>Histopathology</i> , 2015, 67, 62-69.	2.9	12
96	Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years. <i>PLoS ONE</i> , 2015, 10, e0131158.	2.5	22
97	<sup>18</sup> F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. <i>Leukemia and Lymphoma</i> , 2015, 56, 2005-2012.	1.3	28
98	Hormonal dysfunction is frequent in cancer survivors treated with radiotherapy to the head and neck region. <i>Journal of Cancer Survivorship</i> , 2015, 9, 630-640.	2.9	10
99	Fatigue in male lymphoma survivors differs between diagnostic groups and is associated with latent hypothyroidism. <i>Acta Oncologica</i> , 2015, 54, 49-59.	1.8	11
100	Two courses of four weekly infusions of rituximab with or without interferon- $\alpha$ 2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2015, 56, 2598-2607.	1.3	24
101	Chronic fatigue is prevalent and associated with hormonal dysfunction in long-term non-Hodgkin lymphoma survivors treated with radiotherapy to the head and neck region. <i>Leukemia and Lymphoma</i> , 2015, 56, 3306-3314.	1.3	13
102	Heart Failure and Asymptomatic Left Ventricular Systolic Dysfunction in Lymphoma Survivors Treated With Autologous Stem-Cell Transplantation: A National Cross-Sectional Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2683-2691.	1.6	44
103	Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. <i>Haematologica</i> , 2015, 100, 238-245.	3.5	87
104	Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1742-1749.	1.3	17
105	Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma. <i>Acta Radiologica</i> , 2015, 56, 152-158.	1.1	41
106	Discovery of Recurrent Mutations Associated with Chemo-Immunotherapy Relapse in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 110-110.	1.4	1
107	Bone mineral density of the left femoral neck in lymphoma survivors treated with high dose therapy with autologous stem cell support.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20612-e20612.	1.6	0
108	Factors related to unemployment in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20641-e20641.	1.6	0

#	ARTICLE	IF	CITATIONS
109	A national study on conditional survival and excess mortality after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.. Journal of Clinical Oncology, 2015, 33, 8598-8598.	1.6	0
110	Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin®) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL). Blood, 2015, 126, 5118-5118.	1.4	0
111	A Gene Panel, Including LRP12, Is Frequently Hypermethylated in Major Types of B-Cell Lymphoma. PLoS ONE, 2014, 9, e104249.	2.5	13
112	High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. Leukemia and Lymphoma, 2014, 55, 2319-2327.	1.3	9
113	Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood, 2014, 123, 1051-1054.	1.4	49
114	Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy. Leukemia and Lymphoma, 2014, 55, 288-295.	1.3	11
115	Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma. Epigenetics, 2014, 9, 428-436.	2.7	29
116	Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma. Acta Oncologica, 2014, 53, 680-687.	1.8	17
117	Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma. PLoS ONE, 2014, 9, e91031.	2.5	19
118	A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma. Blood, 2014, 124, 3094-3094.	1.4	3
119	Somatic Mutations in E3 Ubiquitin Ligase Deltex 1 Are Associated with Survival in Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 1688-1688.	1.4	0
120	Characterization of the Microrna Expression Profiles of Paired Primary and Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) By Next-Generation Sequencing. Blood, 2014, 124, 1626-1626.	1.4	7
121	Perifollicular Variant of Peripheral T-Cell Lymphoma, UNS: A Distinct Lymphoma Type with Cytogenetic and Clinical Findings Different from Those of Angio-Immunoblastic Lymphoma. Blood, 2014, 124, 3013-3013.	1.4	0
122	Plasma Affinity Proteomic Immunoprofiling As a Novel Prognostic Tool in High Risk Diffuse Large B-Cell Lymphoma Patients: A Nordic Lymphoma Group Study. Blood, 2014, 124, 1618-1618.	1.4	0
123	Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Annals of Oncology, 2013, 24, 1385-1392.	1.2	99
124	A Randomized Study of Interferon $\gamma$ Versus No Treatment as Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Patients With Relapsed Lymphoma. Oncologist, 2013, 18, 1189-1189.	3.7	5
125	Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome. European Journal of Haematology, 2013, 91, 332-338.	2.2	10
126	Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Leukemia and Lymphoma, 2013, 54, 2205-2214.	1.3	18



#	ARTICLE	IF	CITATIONS
127	Identification of Highly Methylated Genes across Various Types of B-Cell Non-Hodgkin Lymphoma. PLoS ONE, 2013, 8, e79602.	2.5	16
128	Phase II Study Of Anti-CD19 Antibody Drug Conjugate (SAR3419) In Combination With Rituximab: Clinical Activity and Safety In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT01470456). Blood, 2013, 122, 4395-4395.	1.4	10
129	The Use Of Plerixafor In Hard-To-Mobilize Lymphoma and Multiple Myeloma Patients Not Only Provide Sufficient Numbers Of Pbpccs To Proceed To High Dose Therapy, But Also Have a Positive Impact On Survival. Blood, 2013, 122, 5517-5517.	1.4	1
130	Dose-Dense Chemoimmunotherapy and Early Central Nervous System Prophylaxis For High-Risk Diffuse Large B-Cell Lymphoma. "Preliminary Results From a Nordic Phase II Study. Blood, 2013, 122, 849-849.	1.4	2
131	Global Profiling Of Outcome Associated Alternative Splicing Events and Gene Expression In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 75-75.	1.4	0
132	High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy. European Journal of Haematology, 2012, 89, 395-402.	2.2	11
133	Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma. Leukemia and Lymphoma, 2012, 53, 1934-1944.	1.3	22
134	The Norwegian experience with penicillin G plus an aminoglycoside as initial empiric therapy in febrile neutropenia; a review. Acta Oncologica, 2012, 51, 433-440.	1.8	10
135	The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: A study of 826 cases from the International Peripheral T-cell Lymphoma Project. American Journal of Hematology, 2012, 87, 790-794.	4.1	38
136	Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. British Journal of Haematology, 2012, 156, 225-233.	2.5	116
137	Alternative Splicing and Expression of Class II Tubulin Beta (TUBB2B) Are Associated with Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2012, 120, 1557-1557.	1.4	1
138	Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group. Blood, 2012, 120, 794-794.	1.4	1
139	Use of exon-based transcriptome profiling to identify novel signaling pathways and survival-associated genes in diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2012, 30, 8074-8074.	1.6	0
140	High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. British Journal of Haematology, 2011, 152, 600-610.	2.5	44
141	Frailty Modeling of the Bimodal Age-Related Incidence of Hodgkin Lymphoma in the Nordic Countries. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1350-1357.	2.5	17
142	Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood, 2011, 117, 3402-3408.	1.4	376
143	T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab. Clinical Cancer Research, 2011, 17, 4136-4144.	7.0	42
144	High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01). Blood, 2011, 118, 331-331.	1.4	3

#	ARTICLE	IF	CITATIONS
145	Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab. <i>Blood</i> , 2011, 118, 1641-1641.	1.4	5
146	Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type. <i>Haematologica</i> , 2010, 95, 1334-1341.	3.5	13
147	Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features) Tj ETQq1 1 0.784314 rgBT/O	4.1	7
148	Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <math>\geq 65</math> years with poor prognosis histologically aggressive NHL. <i>British Journal of Haematology</i> , 2010, 149, 237-243.	2.5	15
149	<i>BCL-2/IgH</i> Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2246-2252.	1.6	47
150	Reply to U. Dörtschbach et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e614-e614.	1.6	1
151	Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2853-2858.	1.6	289
152	R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score $\geq 3$ : Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years.. <i>Blood</i> , 2010, 116, 2805-2805.	1.4	2
153	Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy-Associated T-Cell Lymphoma: a Prospective Study by the Nordic Lymphoma Group (NLG-T-01). <i>Blood</i> , 2010, 116, 3565-3565.	1.4	4
154	Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01). <i>Blood</i> , 2010, 116, 3566-3566.	1.4	5
155	A Novel Cancer Vaccine Strategy In Previously Untreated Patients with Stage III/IV Follicular Lymphoma Generates Tumor-Reactive T Cells and Clinical Response. <i>Blood</i> , 2010, 116, 1804-1804.	1.4	0
156	Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmunotherapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study. <i>Blood</i> , 2010, 116, 3107-3107.	1.4	0
157	High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Dose-Dense Chemoimmunotherapy and Systemic CNS Prophylaxis. Results From a Nordic Phase II Study. <i>Blood</i> , 2010, 116, 4142-4142.	1.4	1
158	Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. <i>Blood</i> , 2009, 113, 2298-2301.	1.4	75
159	Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group. <i>Leukemia and Lymphoma</i> , 2008, 49, 102-112.	1.3	60
160	Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2008, 112, 475-475.	1.4	1
161	R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score $\geq 3$ : Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years. <i>Blood</i> , 2008, 112, 3604-3604.	1.4	0
162	Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 711-717.	3.0	16

#	ARTICLE	IF	CITATIONS
163	Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica, 2007, 92, 139-140.	3.5	95
164	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood, 2007, 109, 4599-4606.	1.4	226
165	Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogeneticâ€‘pathologicâ€‘clinical correlations. Journal of Cancer Research and Clinical Oncology, 2007, 133, 455-470.	2.5	15
166	Gene Expression Signatures Predict Overall Survival in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.. Blood, 2007, 110, 348-348.	1.4	11
167	BCL-2/IgH PCR Values at the End of Induction Treatment Are Not Predictive for Progression Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized Phase III Intergroup Trial.. Blood, 2007, 110, 791-791.	1.4	0
168	Quality of life after total or partial gastrectomy for primary gastric lymphoma. Acta OncolÃ³gica, 2006, 45, 202-209.	1.8	9
169	Vitamin D deficiency in patients operated on for gastric lymphoma. Scandinavian Journal of Gastroenterology, 2006, 41, 673-681.	1.5	5
170	Molecular Diagnosis of Burkitt's Lymphoma. New England Journal of Medicine, 2006, 354, 2431-2442.	27.0	824
171	Testicular Diffuse Large B-Cell Lymphoma of Activated B-Cell Subtype Is Frequently Associated with Clonally Related Non-Follicular Small B-Cell Lymphoma in the Bone Marrow.. Blood, 2006, 108, 2042-2042.	1.4	1
172	Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkinâ€™s Lymphoma in Elderly Patients.. Blood, 2006, 108, 210-210.	1.4	6
173	SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).. Blood, 2006, 108, 2718-2718.	1.4	11
174	Dose-Dense Induction Followed by Autologous Stem Cell Transplant (ASCT) as 1st Line Treatment in Peripheral T-Cell Lymphomas (PTCL) - A Phase II Study of the Nordic Lymphoma Group (NLG).. Blood, 2006, 108, 401-401.	1.4	14
175	Standard CHOP-21 as First Line Treatment for Elderly Patients with Hodgkinâ€™s Lymphoma.. Blood, 2006, 108, 4675-4675.	1.4	0
176	Intensifying Methotrexate (MTX) Dosage Reduces Treatment Failure in Adults with Burkitt or Burkitt-Like Leukaemia/Lymphoma (BL) Treated with an Adapted BFM Protocol.. Blood, 2006, 108, 2438-2438.	1.4	11
177	Enteropathy-Type T-Cell Lymphoma: Clinical Features of a Series of 62 Cases. Jan Delabie, Harald Holte, Andrew Lister and Julie Vose for the International T-Cell Lymphoma Project.. Blood, 2006, 108, 2459-2459.	1.4	0
178	G-banding and molecular cytogenetic analyses of marginal zone lymphoma. British Journal of Haematology, 2005, 130, 890-901.	2.5	28
179	Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkinâ€™s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.. Blood, 2005, 106, 16-16.	1.4	17
180	Outcome of Patients &gt; Age 40 with Burkitt Lymphoma (BL) Treated with Aggressive Chemotherapeutic Regimens: Results from the International Burkitt Lymphoma Collaborative Group.. Blood, 2005, 106, 928-928.	1.4	6

#	ARTICLE	IF	CITATIONS
181	Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. <i>New England Journal of Medicine</i> , 2004, 351, 2159-2169.	27.0	1,293
182	Long-Term Complete Molecular Remissions in Untreated Symptomatic Follicular Lymphoma Treated with Rituximab as Single Agent and in Combination with Interferon-alpha-2a: Analysis of Minimal Residual Disease in the Randomized Phase II Study M39035. <i>Blood</i> , 2004, 104, 1393-1393.	1.4	1
183	High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA. <i>Blood</i> , 2004, 104, 697-697.	1.4	0
184	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. <i>Cancer Cell</i> , 2003, 3, 185-197.	16.8	848
185	Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. <i>Journal of Experimental Medicine</i> , 2003, 198, 851-862.	8.5	1,002
186	CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. <i>Blood</i> , 2003, 101, 3840-3848.	1.4	191
187	The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2002, 346, 1937-1947.	27.0	3,474
188	High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional-Dose Consolidation/Maintenance Therapy as Postremission Therapy for Adult Patients With Lymphoblastic Lymphoma: Results of a Randomized Trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. <i>Journal of Clinical Oncology</i> , 2001, 19, 2927-2936.	1.6	109
189	Testicular lymphoma is associated with a high risk of extranodal recurrence. <i>Cancer</i> , 2000, 89, 713-713.	4.1	7
190	Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in b-cell non-Hodgkin's lymphoma. <i>International Journal of Cancer</i> , 2000, 89, 313-324.	5.1	25
191	Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. <i>Lancet</i> , The, 2000, 356, 1384-1391.	13.7	402
192	Late Medical Sequelae After Therapy for Supradiaphragmatic Hodgkin's Disease. <i>Acta Oncologica</i> , 1999, 38, 511-515.	1.8	22
193	Prognostic Value of Lymphoma-specific S-Phase Fraction Compared with that of Other Cell Proliferation Markers. <i>Acta Oncologica</i> , 1999, 38, 495-503.	1.8	29
194	Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 422-426.	2.3	23
195	A Prognostic Score for Advanced Hodgkin's Disease. <i>New England Journal of Medicine</i> , 1998, 339, 1506-1514.	27.0	1,553
196	Immunomagnetic Purging of Lymphoma Cells from Autografts. <i>Stem Cells and Development</i> , 1996, 5, 561-562.	1.0	3
197	Fat replacement of Hodgkin disease of bone marrow after chemotherapy: report of three cases. <i>Skeletal Radiology</i> , 1996, 25, 671-674.	2.0	11
198	Purging of Tumor Cells from Leukapheresis Products: Experimental and Clinical Aspects. <i>Stem Cells and Development</i> , 1996, 5, 427-436.	1.0	23

#	ARTICLE	IF	CITATIONS
199	Leukemic blasts with markers of four cell lineages in Down's syndrome (â€œmegakaryoblastic leukemiaâ€). Medical and Pediatric Oncology, 1993, 21, 254-258.	1.0	29
200	Expression of CD18 (integrin $\alpha$ 2chain) correlates with prognosis in malignant B cell lymphomas. British Journal of Haematology, 1993, 83, 392-398.	2.5	16
201	Functional properties of CD19 B lymphocytes positively selected from buffy coats by immunomagnetic separation. European Journal of Immunology, 1990, 20, 201-206.	2.9	109
202	Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens. European Journal of Immunology, 1989, 19, 1221-1225.	2.9	28
203	Levels of myc protein, as analyzed by flow cytometry, correlate with cell growth potential in malignant b-cell lymphomas. International Journal of Cancer, 1989, 43, 164-170.	5.1	15
204	Ki67 and 4F2 antigen expression as well as dna synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma. International Journal of Cancer, 1989, 44, 975-980.	5.1	36
205	Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets. International Journal of Cancer, 1988, 42, 521-528.	5.1	21
206	Downregulation of c-myc RNA is not a prerequisite for reduced cell proliferation, but is associated with G1 arrest in B-lymphoid cell lines. Experimental Cell Research, 1987, 172, 84-91.	2.6	17
207	Transforming growth factor type $\beta$ 2 (TGF $\beta$ 2) inhibits G1 to S transition, but not activation of human B lymphocytes. Experimental Cell Research, 1987, 171, 213-222.	2.6	101
208	Progressive loss of vision in patients with high-grade non-Hodgkin's lymphoma. Cancer, 1987, 60, 2521-2523.	4.1	10
209	The activation-associated antigen 4f2 predicts patient survival in low-grade b-cell lymphomas. International Journal of Cancer, 1987, 39, 590-594.	5.1	23